Clinical observation on the target therapy of Rh-endostin, combined with chemotherapy in advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 12, Issue 7, 2009, Pages 780-784

  Mu, Haiyu ^a   Shen, Chunyan ^a   Feng, Yiling ^a  

^a Affiliated Hospital of Tianjin Armed Police College   (China)

Author keywords

Chemotherapy; Lung neoplasms; Rh endostin; Target therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ENDOSTATIN; RECOMBINANT HUMAN ENDOSTIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ST SEGMENT; T WAVE; THROMBOCYTOPENIA; VOMITING;

EID: 70349318008     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.07.007     Document Type: Article

References (23)

1. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non small cell lung cance. J Clin Oncol, 2002, 20(21): 4285-4291. (Pubitemid 35266288)
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-samall cell lung cancer. N Engl J Med, 2002, 346(2): 92-98. (Pubitemid 34438899)
3. Cheng G. Progress of clinical research in "tailor" chemotherapy fou non-small-cell lung cancer. Chin J Cancer, 2008, 11(1): 10-13.
4. Ai XH, Lu S. Advances of maintenance chemotherapy on advanced non-small cell lung cancer. Chin J Cancer, 2008, 11(1): 14-16. 2008, 11(1): 14-16.] (Pubitemid 351588854)
5. Huang GC, Chen LB. Antiangiogenesis therapy and normalization of tumor vasculature and microenvironment. Chin J Cancer Bio, 2008, 15(3): S5-S8.
6. Zhou QH, Sun Y. More attention should be devoted to molecular target therapy of lung cancer in our country. Chin J Lung Cancer, 2004, 7(4): 267-269.
7. Li B, Wu XY, Zhou H, et al. Acid induced unfolding mechanism of recombinant human endostatin. Biochemistey, 2004, 43(9): 2550-2557. (Pubitemid 38327850)
8. Ling Y, Yang Y, Lu N, et al. Endostar, a novel recombinant human endostating, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/FLK-1 of endothelial cells. Biochem Biophys Res Commun, 2007, 361(1): 79-84.
9. Yang L, Wang JW, Tang ZHM, et al. A phase I clinical trial for recombinant human endostatin. Chin J New Drugs, 2004, 13(6): 548-553.
10. Yang L, Wang JW, Cui CX, et al. Rh-endostatin (YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer: a multicenter phase II trial. Chin J New Drugs, 2005, 14(2): 204-207.
11. Wang JW, Sun Y. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer, 2005, 84(4): 283-290. NP NSCLC 2005, 84(4): 283-290.] (Pubitemid 41206392)
12. Liu YY. Phase III clinical trial of recombinant human endostatin in the treatment for advanced non-small cell lung cancer patients. Bul Chin Cancer, 2005, 14(6): 389-400.
13. Huang C, Li K, Niu RF, et al. Circulating endothelial cells in the peripheral blood of advanced NSCLC patients. Chin J Oncol, 2006, 28(10): 780-784. 2006, 28(10): 780-784.] (Pubitemid 44240889)
14. Teng JJ, Han BH, Shen J, et al. Clinical observation of chemotherapy combined endostar in advanced non-small cell lung cancer. Chin Clin Oncol, 2008, 13(2): 171-175.
15. Qin SK, Liu XF, Wang L, et al. Clinical study of endostar combined with chemotherapy for the multiple kind of advanced malignancies except lung cancer. Chin Clin Oncol, 2007, 12(10): 728-735.
16. Sun Y. WHO confirmed cancer is a kind of chronic disease. Clinical Oncology. Beijing: Chinese Electronic Medical Audio and Video Publishing House, 2007, 6: 1-4.
17. Robert FO, Herbst RS, Colson YL, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening- a report from the American society of clinical oncology. J Clin Oncol, 2007, 25(1): 1-17.
18. Sun Y. Recent trends of tumor therapy. Clin Med J, 2006, 4(2): 1-3.
19. Cohen MH, Gootenberg J. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncoloqist, 2007, 12(6): 713-718. (Pubitemid 47036205)
20. Ma SH, Xu K, Xiao ZW, et al. Peripheral lung cancer: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and cyclin D1 expression. Clin Imaging, 2007, 31(3): 165-177. (Pubitemid 46601798)
21. Huang C, Wang LC, Xiao JY, et al. Analysis of cavitation of advanced NSCLC treated by rh-eadostatin combined with NIP chemotherapy. Chin J Oncol, 2008, 30(9): 712-715.
22. Sun Y, Shi YK. Manual of medical oncology (5th edition). Beijing: People Health Publishing House, 2007, 5: 22-27.
23. Herbst RS, Prager D, Herman R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 2005, 23(25): 5892. (Pubitemid 46300205)